Yong-Chan Kim
Directeur/Membre du Conseil chez BAUDAX BIO, INC.
Fortune : 50 $ au 30/04/2024
Profil
Yong-Chan Kim is the founder and current Chief Executive Officer & Director of TeraImmune, Inc., which is founded in 2016.
He is also currently an Independent Director at Baudax Bio, Inc. since 2023.
Dr. Kim holds a doctorate degree from Chungnam National University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/09/2023 | 4 520 ( 16,69% ) | 50 $ | 30/04/2024 |
Postes actifs de Yong-Chan Kim
| Sociétés | Poste | Début |
|---|---|---|
| BAUDAX BIO, INC. | Directeur/Membre du Conseil | 03/07/2023 |
TeraImmune, Inc.
 TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Fondateur | 01/01/2016 |
Formation de Yong-Chan Kim
| Chungnam National University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BAUDAX BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |